Janssen-Cilag, a subsidiary of Johnson & Johnson, is planning to expand its research and development operations in India.
According to a press release, the company expects to increase the capacity of its research and early discovery laboratories in Mumbai from 50 to approximately 100 scientists by the end of 2007. In addition, its clinical pharmaceutical research operations will also expand, as part of the company's ongoing commitment to develop products for use in the Indian marketplace.
Janssen-Cilag India markets products in a number of therapeutic areas, including central Nervous system (CNS), Oncology, and Over the Counter (OTC) therapies.